Mentice Secures $642,000 Order from a Top 20 Global MedTech Company in Interventional Cardiology
23 maj, 2025
Mentice AB (publ), a globally recognized leader in simulation solutions for image-guided interventional therapies, today announced a $642,000 order from a top 20 global Med Tech company, a long-standing and valued customer. This order highlights the increasing demand for simulation-based training solutions to support clinical education, enhance procedural proficiency, and improve patient safety in interventional cardiology.
“We are proud to support our partner in advancing procedural training and patient care,” said Frans Venker, CEO of Mentice. “This order reaffirms the growing reliance on simulation-based training and the strong commitment from medical technology companies to advance procedural safety and innovation.”
This order further strengthens Mentice position as a trusted partner for global healthcare innovators. Through its advanced simulation solutions, Mentice remains dedicated to delivering evidence-based, clinically relevant solutions that support healthcare providers and MedTech companies in facilitating educational initiatives that drive progress in interventional therapies and optimize patient care."
The order will be recognized under Mentice Medical Device Industry division in the coming months of 2025, contributing to the company’s growth strategy and expanding its presence in the market for interventional cardiology training solutions.
Mentice definition of a Top 20 Medical Technology company can be found here: https://www.beckershospitalreview.com/innovation/100-largest-medtech-companies.html
For more information, please contact:
Frans Venker, CEO, Mentice
Email: frans.venker@mentice.com
Mobile +46 (0) 735 25 30 81
About Mentice
Mentice (STO: MNTC) is the world leader in proficiency based simulation solutions for image guided interventional therapies. Our solutions help healthcare professionals acquire, retain, and enhance their procedural skills driving improved productivity and outcomes. Mentice solutions are scientifically validated and have been specifically developed for healthcare providers and the medical device industry. Neurovascular, cardiovascular, and peripheral interventions are just some of the clinical areas covered by our solutions. Learn more about the features and benefits of Mentice solutions at: www.mentice.com
Marketplace| Nasdaq First North Growth Market, Stockholm | Ticker symbol MNTC
Certified Adviser| FNCA Sweden AB
This information is information that Mentice is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-05-23 11:10 CEST.
Attachments
Mentice Secures $642,000 Order from a Top 20 Global MedTech Company in Interventional Cardiology
Ämnen i artikeln
Mentice Secures $642,000 Order from a Top 20 Global MedTech Company in Interventional Cardiology
23 maj, 2025
Mentice AB (publ), a globally recognized leader in simulation solutions for image-guided interventional therapies, today announced a $642,000 order from a top 20 global Med Tech company, a long-standing and valued customer. This order highlights the increasing demand for simulation-based training solutions to support clinical education, enhance procedural proficiency, and improve patient safety in interventional cardiology.
“We are proud to support our partner in advancing procedural training and patient care,” said Frans Venker, CEO of Mentice. “This order reaffirms the growing reliance on simulation-based training and the strong commitment from medical technology companies to advance procedural safety and innovation.”
This order further strengthens Mentice position as a trusted partner for global healthcare innovators. Through its advanced simulation solutions, Mentice remains dedicated to delivering evidence-based, clinically relevant solutions that support healthcare providers and MedTech companies in facilitating educational initiatives that drive progress in interventional therapies and optimize patient care."
The order will be recognized under Mentice Medical Device Industry division in the coming months of 2025, contributing to the company’s growth strategy and expanding its presence in the market for interventional cardiology training solutions.
Mentice definition of a Top 20 Medical Technology company can be found here: https://www.beckershospitalreview.com/innovation/100-largest-medtech-companies.html
For more information, please contact:
Frans Venker, CEO, Mentice
Email: frans.venker@mentice.com
Mobile +46 (0) 735 25 30 81
About Mentice
Mentice (STO: MNTC) is the world leader in proficiency based simulation solutions for image guided interventional therapies. Our solutions help healthcare professionals acquire, retain, and enhance their procedural skills driving improved productivity and outcomes. Mentice solutions are scientifically validated and have been specifically developed for healthcare providers and the medical device industry. Neurovascular, cardiovascular, and peripheral interventions are just some of the clinical areas covered by our solutions. Learn more about the features and benefits of Mentice solutions at: www.mentice.com
Marketplace| Nasdaq First North Growth Market, Stockholm | Ticker symbol MNTC
Certified Adviser| FNCA Sweden AB
This information is information that Mentice is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-05-23 11:10 CEST.
Attachments
Mentice Secures $642,000 Order from a Top 20 Global MedTech Company in Interventional Cardiology
Ämnen i artikeln
Flat Capital
Nya bolåneregler
Analys
Fonder
ETF:er
Flat Capital
Nya bolåneregler
Analys
Fonder
ETF:er
Marknadsöversikt
1 DAG %
Senast
1 mån
